These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 15539918

  • 1. Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.
    Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Caricato M, La Cesa A, Grilli C, Verzì A, Coppola R, Tonini G.
    Oncology; 2004; 67(2):135-42. PubMed ID: 15539918
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H.
    J Clin Oncol; 2002 Apr 01; 20(7):1721-8. PubMed ID: 11919227
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
    Kamoshida S, Matsuoka H, Ishikawa T, Maeda K, Shimomura R, Inada K, Tsutsumi Y.
    Jpn J Clin Oncol; 2004 Oct 01; 34(10):594-601. PubMed ID: 15591457
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
    Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, Stoehlmacher J, Lenz HJ.
    Cancer Res; 2000 Jul 01; 60(13):3493-503. PubMed ID: 10910061
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
    Noda E, Maeda K, Inoue T, Fukunaga S, Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K, Yamada N, Yashiro M, Ohira M, Ishikawa T, Hirakawa K.
    Hepatogastroenterology; 2012 Jul 01; 59(113):130-3. PubMed ID: 21940361
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA, Vainer B, Witton CJ, Jørgensen JT, Sørensen JB.
    Acta Oncol; 2008 Jul 01; 47(6):1054-61. PubMed ID: 18607850
    [Abstract] [Full Text] [Related]

  • 9. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K, Karlberg M, Edler D, Hallström M, Ragnhammar P.
    Clin Colorectal Cancer; 2013 Jun 01; 12(2):128-35. PubMed ID: 23276521
    [Abstract] [Full Text] [Related]

  • 10. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, Capellá G, Villanueva A.
    J Clin Oncol; 2006 Apr 01; 24(10):1603-11. PubMed ID: 16575011
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H, Iinuma H, Watanabe T.
    Oncol Rep; 2008 Mar 01; 19(3):729-35. PubMed ID: 18288408
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P.
    Clin Cancer Res; 2004 Sep 01; 10(17):5880-8. PubMed ID: 15355920
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Häusler P, Ott K, Behnke D, Staib L, Beger HG, Link KH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4116-24. PubMed ID: 14519634
    [Abstract] [Full Text] [Related]

  • 17. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.
    Magy Onkol; 2007 Sep 15; 51(2):113-25. PubMed ID: 17660867
    [Abstract] [Full Text] [Related]

  • 18. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.
    Ohrling K, Edler D, Hallström M, Ragnhammar P, Blomgren H.
    J Clin Oncol; 2005 Aug 20; 23(24):5628-34. PubMed ID: 16009948
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
    Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, Påhlman L, Lindmark G, Blomgren H.
    Clin Cancer Res; 2000 Feb 20; 6(2):488-92. PubMed ID: 10690528
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
    Oi K, Makino M, Ozaki M, Takemoto H, Yamane N, Nakamura S, Ikeguchi M, Kaibara N.
    Anticancer Res; 2004 Feb 20; 24(1):273-9. PubMed ID: 15015608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.